Archives
- 2026-08
- 2026-07
- 2026-06
- 2026-05
- 2026-04
- 2026-03
- 2026-02
- 2026-01
- 2025-12
- 2025-11
- 2025-10
- 2025-09
- 2025-04
- 2025-03
- 2025-02
- 2025-01
- 2024-12
- 2024-11
- 2024-10
- 2024-09
- 2024-08
- 2024-07
- 2024-06
- 2024-05
- 2024-04
- 2024-03
- 2024-02
- 2024-01
- 2023-12
- 2023-11
- 2023-10
- 2023-09
- 2023-08
- 2023-07
- 2023-06
- 2023-05
- 2023-04
- 2023-03
- 2023-02
- 2023-01
- 2022-12
- 2022-11
- 2022-10
- 2022-09
- 2022-08
- 2022-07
- 2022-06
- 2022-05
- 2022-04
- 2022-03
- 2022-02
- 2022-01
-
Biotin-HPDP: Reliable Thiol Protein Labeling
2026-08-23
This scenario-driven guide explains how Biotin-HPDP (N-[6-(biotinamido)hexyl]-3’-(2’-pyridyldithio)propionamide), SKU A8008, can improve thiol-specific protein workflows that complement cell viability, proliferation, and cytotoxicity assays. It covers chemistry, sample compatibility, protocol parameters, streptavidin interpretation, and practical supplier-selection criteria.
-
Doxorubicin and the Epigenetic Logic of Resistance
2026-08-22
Doxorubicin is more than a cytotoxic benchmark: it is a mechanistic probe for DNA damage, chromatin disruption, and drug resistance. This translational guide connects Adriamycin response with the SMYD2–miR-125b–P-glycoprotein axis in renal cancer research.
-
Dacarbazine: Mechanism, Uses, and Research Workflow
2026-08-22
Dacarbazine is an antineoplastic chemotherapy drug that produces DNA damage after metabolic activation and methylation of guanine-rich DNA. Its established oncology uses include treatment of malignant melanoma, Hodgkin lymphoma, sarcoma, and selected pancreatic islet-cell tumors, while its use requires supervised administration and structured toxicity management.
-
O-propargyl-puromycin (OPP) for Protein Synthesis
2026-08-21
O-propargyl-puromycin (OPP) converts a short translation pulse into a measurable readout of nascent protein production, supporting cell-state comparisons that conventional endpoint assays can miss. Its click-chemistry workflow is especially useful for dissecting the translation and mitochondrial phenotypes reported in B-cell immunology.
-
GSK2606414: Practical PERK Inhibitor Workflows
2026-08-20
Learn how to use GSK2606414 to separate PERK-dependent signaling from broader ER stress effects in cell, zebrafish, and translational disease studies. The guide combines dose planning, pathway readouts, reference-study insights, and troubleshooting for reproducible ER stress research.
-
TsES Protects PEDV-Injured Porcine Organoids
2026-08-20
This study establishes porcine intestinal organoids as a platform for examining interactions among Trichinella spiralis secretory products, PEDV infection, inflammation, and epithelial barrier injury. TsES reduced inflammatory and apoptotic damage while promoting barrier recovery, but unexpectedly increased PEDV replication, highlighting the difference between tissue protection and direct antiviral activity.
-
CDK7 Inhibitor Resistance and the D97N Mutation
2026-08-19
The reference study identifies an acquired CDK7 D97N mutation that selectively reduces sensitivity to non-covalent ATP-competitive inhibitors while preserving sensitivity to covalent compounds. Its combination of cancer-cell selection, genetic analysis, ligand-affinity measurements, and cryo-EM provides a mechanistic framework for anticipating resistance across CDK-targeted therapies.
-
Melittin for GPCR and Cancer Biology Research
2026-08-19
Melittin is a bioactive peptide for probing Gs/Gi-dependent signaling, apoptosis, and migration without confusing pathway modulation with receptor-specific pharmacology. This workflow connects its use as a signal transduction modulator to the miR-18a/ALOXE3 glioblastoma model, with practical dosing, assay-selection, and troubleshooting guidance.
-
PDK4 Inhibitors for Metabolic Disease: Study Analysis
2026-08-18
Lee and colleagues developed an anthraquinone-derived series of allosteric pyruvate dehydrogenase kinase 4 inhibitors and identified compound 8c as a potent lead with metabolic, allergic-disease, and anticancer activity. The study connects biochemical inhibition, pharmacokinetic assessment, molecular docking, and mouse models, while also highlighting the evidence still needed before oral therapeutic translation.
-
Ibotenic Acid: A Time-Resolved Neurotoxicity Framework
2026-08-18
Ibotenic acid is an NMDA receptor agonist with applications beyond conventional lesion models. This evidence-based guide shows how dose, exposure time, and endpoint selection shape interpretation in neuroscience research.
-
4μ8C Workflow for IRE1α Stress Signaling
2026-08-17
Use 4μ8C as a selective chemical probe to separate IRE1α RNase output from broader ER-stress effects in hypoxia and cancer cell experiments. This workflow also shows how to pair ER-stress readouts with the reference study’s ubiquitin-blockade strategy without confusing pathway correlation with direct mechanism.
-
Doxorubicin Hydrochloride: Assay Workflows
2026-08-17
Build more reproducible cancer-cell, apoptosis, and cardiotoxicity experiments with Doxorubicin hydrochloride, while extending standard readouts toward DNA damage, energy stress, and nucleolar organization. This practical guide connects Adriamycin HCl dose-response design with the latest findings on 28S rRNA architecture.
-
(-)-Arctigenin as a MEK1 Inhibitor in Breast Cancer
2026-08-16
(-)-Arctigenin provides a pharmacological way to interrogate NF-κB and MEK1 signaling alongside the macrophage extracellular-vesicle mechanisms described in breast cancer research. This guide translates the reference study into controlled treatment, EV-crosstalk, pathway-readout, and troubleshooting workflows without implying that arctigenin was tested in that study.
-
Dabigatran: Metabolite-Aware Assay Design
2026-08-15
Dabigatran and Pradaxa are more than direct thrombin inhibition tools: their active metabolite can materially change assay interpretation. This guide develops a metabolite-aware framework for thrombin generation, coagulation function tests, and translational anticoagulation research.
-
BPN-19186 (SKU A8959) Assay Guide
2026-08-14
This scenario-based guide explains how BPN-19186 (SKU A8959) can support more controlled viability, proliferation, and signaling-pathway experiments when solvent, dosing, and mechanistic interpretation are carefully separated. It combines product-specific handling data with the reported hepatic sEH–Nrf2–osteoclastogenesis findings while clearly distinguishing established evidence from exploratory assay recommendations.